We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer

By LabMedica International staff writers
Posted on 26 Nov 2014
Print article
Image: The Isolation by Size of Epithelial Tumor cells (ISET) technology (Photo courtesy of Rarecells Diagnostics).
Image: The Isolation by Size of Epithelial Tumor cells (ISET) technology (Photo courtesy of Rarecells Diagnostics).
Chronic obstructive pulmonary disease (COPD) is a risk factor for lung cancer and migration of circulating tumor cells (CTCs) into the blood stream is an early event that occurs during carcinogenesis.

The overall prognosis of lung cancer remains dismal, in particular at advanced stages of non-small-cell lung cancer (NSCLC) patients and one of the reasons for the poor prognosis in NSCLC patients is the absence of routine, easy to perform and low cost methods that allow detection of asymptomatic early-stage tumors.

Scientists at the Pasteur Hospital, (Nice, France) enrolled in a prospective study 245 subjects without cancer, including 168 (68.6%) COPD patients, and 77 subjects without COPD (31.4%), which included 42 control smokers and 35 non-smoking healthy individuals, between June 2008 and April 2012. CTCs were identified by cytomorphological analysis and characterized by studying their expression of epithelial and mesenchymal markers.

CTC detection was performed using The Isolation by Size of Epithelial Tumor cells (ISET) technology (Rarecells Diagnostics; Paris, France). The ISET method is a blood filtration-based approach, which enriches on a polycarbonate membrane cells larger than eight micrometers. The membrane was processed both for immunocytochemistry and for May Grünwald Giemsa (MGG) staining for cytological analysis. Immunocytochemistry was performed using double immunolabeling. Using ISET, patients were considered positive for CTCs based on cytopathological analysis of the isolated cells and detection of cells with characteristic malignant features determined according to previously defined criteria.

CTCs were detected in 5 of the 168 patients (3%) of COPD patients. Isolated cells with benign cytomorphological features were detected by ISET in 3 out of 168 patients (1.8%) of COPD patients. None of these three patients and none of the other 160 patients with COPD, and with no pathological cells at baseline in the blood, were shown to develop a lung nodule, as demonstrated by a yearly computerized tomography (CT)-scan during the subsequent follow-up starting with the first blood filtration.

The authors concluded that a sensitive and diagnostic CTC detection approach can find CTCs in patients “at risk” of developing lung cancer without a detectable nodule by CT scan. A small fraction of COPD patients were found to have CTCs one to four years before identification of a lung nodule by imaging. In five patients, the lung cancer was diagnosed at an early stage (IA) allowing prompt surgical resection; they were then shown to be without tumor recurrence and without CTCs 16 months after surgery. The study was published on October 31, 2014, in the journal Public Library of Science ONE.

Related Links:

Pasteur Hospital
Rarecells Diagnostics 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.